Ieramilimab
Подписчиков: 0, рейтинг: 0
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Clinical data | |
| Other names | LAG525 |
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Ieramilimab (development code LAG525) is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.
Ieramilimab's first clinical trial is a Phase I in patients with various solid tumors, in combination with spartalizumab (PDR001), an anti-PD-1 monoclonal antibody has been completed. Recruiting for a phase 2 study in combination with spartalizumab for the treatment of metastatic melanoma is underway.